Candel Therapeutics, Inc. SEC filings CADL
Candel Therapeutics, Inc. has 416 filings in SEC EDGAR's recent list, going back to Feb 16, 2021. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 22, 2025 | — |
| CORRESP | Letter to the SEC | Aug 20, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2025 | — |
| EFFECT | Filing | Aug 12, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2022 | — |
| EFFECT | Filing | Jul 26, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| CORRESP | Letter to the SEC | Jul 26, 2021 | — |
| CERT | Filing | Jul 22, 2021 | — |
| CORRESP | Letter to the SEC | Jul 20, 2021 | — |
| CORRESP | Letter to the SEC | Jul 20, 2021 | — |
| CORRESP | Letter to the SEC | Jul 20, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2021 | — |
| 8-A12B | Filing | Jul 19, 2021 | — |
| CORRESP | Letter to the SEC | Jul 16, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2021 | — |
| CORRESP | Letter to the SEC | Jul 7, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2021 | — |
| DRS/A | Filing | Mar 31, 2021 | — |
| DRSLTR | Filing | Mar 30, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2021 | — |
| DRS | Filing | Feb 16, 2021 | — |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CADL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Needham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841387
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.